Method 4022 patients (>=12 years old) were randomized into 4, 14-day double-blind, placebo-controlled SAR trials to receive MP29-02*, AZE, FP or placebo nasal sprays (all given as 1 spray/nostril bid). 612 patients (>=12 years old) were randomized into a 1-year, open-label, active-controlled, parallel-group chronic rhinitis trial to receive MP29-02* (1 spray/nostril bid) or FP nasal spray (2 sp...

Non-Methane Volatile Organic Compounds (NMVOCs) from domestic aerosol sprays are emerging pollutants and have substantial negative effects on human health the environment. This study, for the first time, carried out quantification of NMVOC emissions from off-the-shelf sprays, at “source” in UK. These sprays contain harmful organic compounds as propellants products. The results showed that t...

FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Allergic Rhinitis Azelastine Hydrochloride Nasal Spray 0.1% and 0.15% is indicated for the relief of the symptoms of seasonal and perennial allergic rhinitis in patients 6 years of age and older. 2 DOSAGE AND ADMINISTRATION 2.1 Seasonal Allergic Rhinitis In children 6 to 11 years of age, the recommended dose of Azelastine Hydrochloride Na...

OBJECTIVES/HYPOTHESIS Sinonasal diseases are often treated with topical agents administered through various application techniques, but few prior studies have examined their distribution to the olfactory mucosa. The purpose of this study was to compare the distribution of nasal irrigations to sprays within the olfactory cleft. STUDY DESIGN Human cadaveric study. METHODS Eight cadaveric head...

Copyright © 2012 Frederick Furness Publishing 14 Nasal sprays that deliver active ingredients using droplets are well-established drug delivery vehicles, both for locally acting and systemic therapies. More recently, though, the pharmaceutical industry has started to turn its attention to delivering dry powders via the nasal route, a step that parallels the introduction of dry powder inhalers (...

Two studies were undertaken to assess the efficacy and safety of three thixotropic nasal sprays (IQM11, IQM12, IQM13) on seasonal allergic rhinitis (SAR). The three nasal sprays differ only with respect to the emulsifying agent used in the formulation. In the prospective, randomized, cross-over pilot study, 16 patients with a history of SAR received 2 x 0.14 ml IQM11 per nostril or no treatment...